An open-label phase I study of the safety of perifosine in combination with sunitinib malate for patients with advanced cancers.
Phase of Trial: Phase I
Latest Information Update: 03 Jun 2015
At a glance
- Drugs Perifosine (Primary) ; Sunitinib (Primary)
- Indications Cancer; Gastrointestinal stromal tumours; Renal cancer
- Focus Adverse reactions
- Sponsors Keryx Biopharmaceuticals
- 27 Feb 2013 Additional lead trial centre added as reported by ClinicalTrials.gov record.
- 06 Apr 2010 Actual end date (1 Oct 2009) added as reported by ClinicalTrials.gov record..
- 06 Apr 2010 Status changed from discontinued to completed as reported by ClinicalTrials.gov record.